Response Results of Abbott’s Investigational Anti-Interleukin-12 (IL-12) Fully Human Monoclonal Antibody in Crohn’s Disease Study
Study Findings:
Results of a Phase II study of Abbott’s ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn’s disease compared to placebo, in one arm of the study.
ABT-874 is an investigational agent designed to target and neutralize IL-12, a known […]